The global sales of pain management devices is estimated to be worth USD 3,019.8 million in 2025 and anticipated to reach a value of USD 5,727.5 million by 2035. Sales are projected to rise at a CAGR of 6.6% over the forecast period between 2025 and 2035. The revenue generated by pain management devices in 2024 was USD 2,855.7 million.
Pain management devices represent a rapidly growing sector within the healthcare industry; advanced solution options have been developed to manage both chronic and acute pain with as little reliance on pharmacological treatment. Neurostimulation devices are the most dominating segment as compared to other pain management devices. It has gained much popularity since these devices are primarily used across different age-demographics of patient to treat different various chronic pain related diseases.
Rising instances of chronic pain diseases worldwide such as neuropathic pain, musculoskeletal pain, cancer pain, migraines, and other chronic pains alongside the increasing burden of opioid addiction have told the need for non-invasive and effective alternatives; hence driving sales in the pain management devices market.
Global Pain Management Devices Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2024 | USD 2,855.7 million |
| Estimated Size, 2025 | USD 3,019.8 million |
| Projected Size, 2035 | USD 5,727.5 million |
| CAGR (2025 to 2035) | 6.6% |
The pain management devices market is expected to be quite optimistic over the next decade, with high acceptance across different age group of patients. Key factors driving growth include an aging global population, a surge in chronic pain disorders, and advancements in device technology. Infusion pumps and ablation devices are of smaller size in terms of market share but also exhibit steady growth as they assist in cancer pain management and localized pain relief, respectively.
Several key drivers drive the growth in the pain management devices market. First, with the increasing occurrence of chronic conditions such as neuropathic pain, arthritis, and back pain, there will be a significant patients' population for effective long-term pain relief solution. For instance, nearly 20% of all adults worldwide report suffering from some form of chronic pain, representing a critical need to develop innovative therapies.
The growing demand for minimal invasiveness therapies is also one of the most driving forces. Non-invasive spinal cord stimulators, transcutaneous electrical nerve stimulators, TENS, which require little time for recovery, minimize the requirement of medicines to be used during therapy, thus reducing dependency. This factor is also responsible for the market growth
Governments as well as healthcare agencies are now applying different strategies for promoting non-pharmacological treatment of pain management as part of a response to opioid misuse and addiction. The general momentum for this change of focus opened up opportunities for the incorporation of devices in pain management.
Continued innovation and growing demand have the market poised for sustainable growth as it addresses a pressing need for pain relief solutions in various parts of the world. A growing prevalence of chronic pain, technological advancements, and global shifts toward non-invasive treatments is driving the market for pain management devices.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The global pain management devices market's compound annual growth rate (CAGR) for the first half of 2024 and 2025 is compared in the table below. This analysis provides important insights into the performance of the industry by highlighting significant shifts and trends in revenue generation.
The first half (H1) is the period from January to June, and the second half (H2) is July to December. In the first half (H1) of the decade from 2024 to 2034, the business is predicted to surge at a CAGR of 7.3%, followed by a slightly lower growth rate of 7.0% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 7.3% (2024 to 2034) |
| H2 | 7.0% (2024 to 2034) |
| H1 | 6.6% (2025 to 2035) |
| H2 | 6.1% (2025 to 2035) |
Moving into the subsequent period, from H1 2025 to H2 2035, the CAGR is projected to decrease slightly to 6.6% in the first half and remain relatively lower at 6.1% in the second half. In the first half (H1) the industry witnessed a decrease of 70 BPS while in the second half (H2), the industry witnessed a decrease of 90 BPS.
Growing Prevalence of Chronic Pain Conditions is driving the Market Growth
One of the critical factors for the growth of the pain management devices market is the increase in the prevalence of chronic pain conditions. Chronic pain disorders affect about over 20% of adults worldwide, among which neuropathic pain, arthritis, and different types of facial pain and migraines are among the leading contributors.
This growing number of patients has created a dire need for proper and long-term treatments-rather than pharmacological treatments. Pain management devices such as neurostimulation systems and infusion pumps confer appropriate relief by addressing the underlying pain mechanisms while minimizing the side effects associated with prolonged medication use.
Moreover, an aging global population accentuates the trends, as older adults are more susceptible to musculoskeletal and degenerative conditions requiring chronic pain management.
Unfortunately, the increase in incidence of lifestyle-disorders such as diabetes and obesity has resulted in further complications related to pain. This has augmented the demand for these devices. Likewise, governments and healthcare organizations promote awareness and early interventions for chronic pain. This is a reason for their encouragement of innovative devices in developed and emerging markets.
Rising Emphasis on Non-Opioid Pain Management Solutions is driving the Pain Management Devices
Non-opioid solutions for pain management are becoming a most important driving force in the market of pain management devices. With the rapid increase in opioid addiction and its associated social and economic cost.
The government, the healthcare system and regulatory agencies are working steadfastly towards creating alternatives for opioid-based pain therapies. Pain management devices such as neurostimulators, TENS, and infusion pumps have appeared as painless alternatives to the management of chronic and acute pain, thus accounting for their large usage.
The opioid epidemic particularly in the United States, has posed threats towards opiod dependency, overdose, and death due to long-term opioid use. Non-pharmacological methods of pain management have been the center stage in the medical community.
Pain management devices focus on the modulation of nerve activity blocking pain signals, or administer localized therapy without affecting the central nervous system. This mechanism limits the need for systemic medications and reduces side effects, hence making these devices a safer option for long-term management of pain.
In addition to the above, the increasing regulatory pressure on prescribing of opioids is an appealing backdrop for market growth. In many regions, tougher guidelines on the use of opioids and reimbursement provisions promoting non-invasive treatments are leading healthcare providers to explore alternative therapies. For instance, several insurance providers today cover neurostimulation devices as part of chronic pain management plans and thus further fuel market growth.
Awareness Programs towards Chronic Pain Management is Creating Opportunities in the Market
The emerging markets have immense growth potential for pain management devices, as the access to healthcare infrastructure and advanced medical technologies is improving rapidly. Countries in Asia-Pacific, Latin America, and the Middle East are witnessing rising healthcare investments, driven by economic growth and increasing awareness of chronic pain management solutions.
In regions like India and China, there is a significant patient pool with chronic pain conditions being increasingly common, provides an enormous untapped market for pain management devices. The government initiatives of improved access to and affordability of healthcare in these regions also encourage advanced medical devices adoption.
Many global players are now interested in expanding in these markets using collaborations, partnership and locally manufactured products, which reduce operational costs and offer superior service. Also, patient preference towards telemedicine and digital healthcare platforms further unlocks the availability of pain management offerings in rural, underserved geography, making such emerging markets more of a growth area in this industry.
High Cost of Pain Management Devices may Restrict Market Growth
Despite the growing growth and effective products in the market for pain management devices, the high cost of these devices continues to be the major barrier towards their widespread use, especially in low- and middle-income countries. Moreover, the ongoing costs of maintaining the devices include replacing batteries and reprogramming them.
These additional costs add up to be burdensome on patients. Even though some countries provide insurance for these devices, coverage is often incomplete in other areas, thus limiting their availability. Neurostimulation devices among other advanced pain management solutions often have significant upfront costs, making them inaccessible to a large segment of the population.
High costs of acquiring and maintaining the devices can also deter their use by healthcare providers. Additionally, a shortage of qualified personnel to run and maintain these devices in some regions adds to the operational burden. These cost-related barriers need to be addressed for the goal of equal access to pain management devices and sustainable market growth.
The global pain management devices industry recorded a CAGR of 3.9% during the historical period between 2020 and 2024. The growth of pain management devices industry was positive as it reached a value of USD 5,727.5 million in 2035 from USD 3,019.8 million in 2025.
The pain management devices market over the last decades had been a highly evolved market, changing from pharmacological treatment to advanced technologies to provide non-invasive and minimally invasive pain relief. Historically, opioid-based medications have been the mainstay of pain management which was heavily prescribed to numerous patients when evidence of well-documented risks of addiction, dependency, and side effects exists.
Finally, in the latter part of the 20th century, developments in TENS devices and neurostimulators were promising enough to initiate developments in device-based pain management treatments. It is because chronic pain conditions affect almost 20% of adults worldwide. Therefore, the market keeps going steady as long as such pain continues.
More recently, devices, including neurostimulation, have dominated this market since they have proven to be effective for neuropathic and musculoskeletal pain. Due to their focused relief without side effects of medication on the entire system, the devices are extremely popular.
Gazing into the future, the future of the devices market for managing pain looks like it will flourish. The increase will be fostered by incessant technological changes, such as fully implantable neurostimulation systems, bioelectronic drugs, and regenerative therapies used to repair the damage done in nerves and replace lost function.
Digital health technology, including remote monitoring systems and telemedicine platforms, will change the management of chronic pain and will make room for real-time therapy adjustments along with increased patient treatment compliance. The aging world population will fuel further demand, since older adults are more susceptible to pain-inducing conditions such as arthritis, degenerative spinal disorders, and cancer.
Tier 1 companies are the industry leaders with 53.7% of the global industry. These companies stand out for having a large product portfolio and a high production capacity. These industry leaders also stand out for having a wide geographic reach, a strong customer base, and substantial experience in manufacturing and having enough financial resources, which enables them to enhance their research and development efforts and expand into new industries. The companies within tier 1 have a good reputation and high brand value.
Prominent companies within tier 1 include Abbott Corporation, Medtronic PLC, Boston Scientific Corporation and Becton, Dickinson and Company
Tier 2 companies are relatively smaller as compared with tier 1 players. The tier 2 companies hold a market share of 17.1% worldwide. These firms may not have cutting-edge technology or a broad global reach, but they do ensure regulatory compliance and have good technology. The players are more competitive when it comes to pricing and target niche markets. Key Companies under this category include Baxter International, Nipro Corporation, B. Braun Melsungen AG among others.
Compared to Tiers 1 and 2, Tier 3 companies offer Pain Management Devices, but with smaller revenue spouts and less influence. These companies mostly operate in one or two countries and have limited customer base. They specialize in specific products and cater to niche markets, adding diversity to the industry.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The market analysis for pain management devices in various nations is covered in the section below. An analysis of important nations in North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and Middle East & Africa of the world has been mentioned below. It is projected that the United States will maintain its leading position in North America through 2035, holding a value share of 88.1%. By 2035, China is expected to experience a CAGR of 7.7% in the Asia-Pacific region.
| Countries | Value CAGR (2025 to 2035) |
|---|---|
| United States | 4.6% |
| Germany | 5.3% |
| UK | 5.0% |
| France | 5.8% |
| China | 7.7% |
| South Korea | 7.0% |
| India | 8.3% |
Germany’s pain management devices market is poised to exhibit a CAGR of 5.3% between 2025 and 2035. The Germany holds highest market share in European market.
The major growth drivers in the market for the country of Germany were its developed healthcare infrastructure and the high prevalence of chronic pain conditions, especially in the aging population. Being one of the strongest economies in Europe, Germany has invested a lot in sectors like innovation in health care and development in medical devices.
It is, therefore, a supportive environment for the growth of this market for pain management devices. Chronic conditions, like arthritis, back pain, and neuropathic disorders, are extremely common among elderly people in Germany, who constitute a huge percentage of its population. The country has the most updated health facilities to handle such conditions with modern pain management solutions like neurostimulation devices, infusion pumps, and TENS devices.
Germany is also a hotbed of medical research and innovation. Many top manufacturers of devices in pain management are headquartered or operating within the country. Apart from incentives for the introduction of innovative medical technology, these companies also enjoy great government support through funding for R&D. Healthcare regulations are very stringent in the country, hence ensuring proper quality and safety of devices, leading to increased confidence among health care providers and patients.
United States is anticipated to show a CAGR of 4.6% between 2025 and 2035. The United States hold maximum revenue share in the North America region.
Misuse of prescription opioids have led to drug overdose and around 108,000 deaths reported in united states due to drugs overdose. Opioid overdose cases contributes around 76% of these overall deaths. This opioid crisis has significant changed way pains are managed thus driving the demand in the pain management devices in the United States.
Such an epidemic, leading to thousands of fatalities and putting the healthcare system to its limits, has forced huge changes in regulations and shifted to treatment schemes using alternative treatment modalities.
These devices include neurostimulation systems, infusion pumps, and TENS units, among others, and have been increasingly used as safer, effective alternatives for opioids. It is now well supported by both government initiatives and healthcare policies since many states demand them as primary treatments for chronic pain disorders.
There is a high percentage of chronic conditions among the millions of Americans who face this condition-about 50 million. Chronic pain, attributed to disorders like arthritis, cancer, and other musculoskeletal disorders, severely burdens the USA healthcare system.
Pain management devices are increasingly being recognized as an integral part of long-term care strategies for these patients. With advanced technologies available, as well as the willingness of healthcare providers to adopt this new technology, significant growth in this market can be observed.
India is anticipated to show a CAGR of 8.3% between 2025 and 2035.
The booming chronic pain conditions and fast development of the healthcare infrastructure are the driving factors for pain management devices market in India. Due to the growing aging population, increased number of sedentary jobs, and the rising prevalence of diabetes and obesity, there is an inevitable rise in chronic conditions like arthritis, back pain, or neuropathic pain, thus creating demand for effective pain management.
However, the Indian market is at a nascent stage compared to developed countries, meaning that it has massive growth potential as awareness about advanced pain management devices increases.
The healthcare system in India has been undergoing drastic changes owing to different government initiatives in making health accessible and affordable. In addition to this, a significant entrance of private healthcare providers has gained traction regarding the introduction of advanced pain management technology in the cities, creating a dual market phenomenon.
The section contains information about the leading segments in the industry. Based on product, the neurostimulation devices segment is expected to account for 43.6% of the global share in 2025.
| By Type | Neurostimulation Devices |
|---|---|
| Value Share (2025) | 43.6% |
The neurostimulation devices segment is projected to be a dominating segment in terms of revenue, accounting for almost 43.6% of the market share in 2025.
These are devices widely accepted for the alleviation of efficient, non-invasive, long-term pain management, especially neuropathic, spinal cord injury, and post-surgical conditions. Neurostimulation drugs are capable of providing good pain relief, without prescription opioids owing to disruption of pain signals sent to the brain before even reaching it via electrical impulses directed at certain nerves or the spinal cord.
An increase in prevalence, a concomitant increased awareness of non-pharmacological modalities of treatment worldwide, and all of those factors have driven the demand for neurostimulation devices.
In addition, technological developments such as minimally invasive surgery in implantology, wireless connectivity, and rechargeable systems alone have made patient convenience and compliance a consideration to spur their continuous uptake. The wide usage in managing pain emanating from quadriplegia as well as other spinal cord injuries reaffirms their strategic position within the market.
| By Application | Neuropathic Pain |
|---|---|
| Value Share (2025) | 61.2% |
The incidence of diabetes is quite high all over the world; in increasing incidence rates of spinal cord injury and chronic nerve disorder there is an ongoing high demand for pain management devices specially designed for neuropathic pain. In the coming years, neuropathic pain is most likely going to seize greater control of pain management devices markets.
Neurostimulation devices like spinal cord stimulators have shown effectiveness in treating neuropathic pain because they disrupt such pain signals from the nervous system. Combined with great success and growing awareness and uptake, neuropathic pain has grown to become the major application within this market. Besides, neuropathic pain requires long-term management in most cases, thus aiding in the ramp-up of demand for implantable and non-invasive pain relief solutions.
In terms of this market, the companies involved are resorting to multiple strategies to retain a competitive position. Strategic partnerships and collaborations with research institutions and healthcare providers are being utilized to broaden their product portfolio. Geographical expansion into the emerging markets has been another strategic priority for these companies, where growth in the healthcare infrastructure and awareness is strong.
Recent Industry Developments in Pain Management Devices Industry Outlook
In terms of type, the industry is divided into neurostimulation devices, infusion pumps and ablation devices.
In terms of application, the industry is segregated into neuropathic pain, musculoskeletal pain, cancer pain, facial pain & migraine among others
In terms of mode of purchase, the industry is divided into prescription and over-the-counter
Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle East and Africa (MEA) have been covered in the report.
The global pain management devices industry is projected to witness CAGR of 6.6% between 2025 and 2035.
The global pain management devices industry stood at USD 2,855.7 million in 2024.
The global pain management devices industry is anticipated to reach USD 5,727.5 million by 2035 end.
China is expected to show a CAGR of 7.7% in the assessment period.
The key players operating in the global pain management devices industry are Abbott Corporation, Medtronic PLC, Boston Scientific Corporation, Becton, Dickinson and Company, Baxter International, Nipro Corporation, B. Braun Melsungen AG, and Moog Inc. Among others
| Estimated Market Size (2024E) | USD 64.5 billion |
|---|---|
| Projected Market Value (2034F) | USD 117.7 billion |
| Value-based CAGR (2024 to 2034) | 6.2% |
| Estimated Size, 2024 | USD 2.7 billion |
|---|---|
| Projected Size, 2034 | USD 3.2 billion |
| Value-based CAGR (2024 to 2034) | 4.1% |
| Market Value for 2024 | USD 13.59 billion |
|---|---|
| Market Value for 2034 | USD 20.5 billion |
| Market CAGR (2024 to 2034) | 4.2% |
| Industry Value in 2023 | USD 59.28 billion |
|---|---|
| Industry Value in 2033 | USD 163.84 billion |
| Industry CAGR (2023 to 2033) | 10.7% |
Explore Therapeutic Device Insights
View Reports
Pain Management Devices Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
